Pacific Biosciences of California, Inc. provided revenue guidance for the fourth quarter and full year 2022. For the quarter, the company expects preliminary unaudited revenue of approximately 27.3 million, representing a decrease of approximately 24% compared with 36.0 million for the fourth quarter of 2021.
For the year, preliminary unaudited annual 2022 revenue is expected to be approximately 128.2 million, representing a decline of 2% from 2021.